Dr. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China; he has served as a speaker and/or consultant for AbbVie, Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, NeuraWell, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, and Viatris; and he is CEO of Braxia Scientific Corp. Dr. Mansur has received research grant support from CIHR, the PSI Foundation, and the Baszucki Brain Research Fund. Dr. Oliveira-Maia has received research grant support from the European Research Council, European Union’s Horizon 2020 Research and Innovation Programme, FEDER, Fundação para a Ciência e Tecnologia; he has received sponsored research support from Compass Pathways, Janssen, and Schuhfried GmBH; and he has served as a speaker and consultant for Angelini, the European Monitoring Centre for Drugs and Drug Addiction, Janssen, MSD, the National Board of Medical Examination at the Portuguese Medical Association and Portuguese Ministry of Health, and Neurolite AG. Dr. Maletic has served as a consultant for AbbVie/Allergan, Acadia Pharmaceuticals, Alfasigma, Alkermes, Biogen, Boehringer Ingelheim, Cerevel Therapeutics, Corium, Intra-Cellular Therapies, Ironshore, Janssen, LivaNova, Lundbeck, Jazz Pharmaceuticals, Neumora, Neurelis, Noven Pharmaceuticals, Otsuka America Pharmaceutical, Pax Medica, Relmada Therapeutics, Sage, Sunovion, Supernus Pharmaceuticals, and Takeda; and he has served on speakers bureaus for AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Otsuka America Pharmaceutical, Sunovion, Supernus Pharmaceuticals, and Takeda. Dr. Suppes has received grants from Cohen Biosciences, Compass Pathways, and Merck; she has served as a consultant for Impel NeuroPharma, Intracellular Therapies, Merck Research Laboratories, Servier (Australia), and Sunovion; she receives royalties from American Psychiatric Association Publishing, Hogrefe Publishing, Jones and Bartlett, and Wolters Kluwer Health (UpToDate); she has stock options with PsiloTec; and she has received CME honoraria from the Clinical Education Alliance, the CME Institute (Physicians Postgraduate Press, Inc.), CMEology, Integrity Continuing Education, Medscape, Novus Medical Education, and Practicing Clinicians Exchange. Dr. Stahl has received research and/or grant support from Acadia, Allergan/AbbVie, Avanir, Boehringer Ingelheim, Braeburn Pharmaceuticals, Daiichi Sankyo Brazil, Eisai, Eli Lilly, Harmony Biosciences, Indivior, Intra-Cellular Therapies, Ironshore, Neurocrine, Otsuka, Pear Therapeutics, Sage, Shire Sunovion, Supernus, and Torrent; he has served as a consultant for AbbVie, Acadia, Alkermes, Allergan, Axsome, Clearview, Done, Eisai Pharmaceuticals, Gedeon Richter, Intra-Cellular Therapies, Karuna Therapeutics, Levo Therapeutics, Lundbeck, NeuraWell, Neurocrine Biosciences, Otsuka, Relmada Therapeutics, Sage Therapeutics, Sunovion, Supernus, Taliaz, Teva, Tris Pharma, and VistaGen; he has served on speakers bureaus for Acadia, Lundbeck, Neurocrine, Otsuka, Servier, Sunovion, and Teva; and he holds options in Delix, Genomind, Lipidio, and NeuraWell. Dr. Rosenblat has received research grant support from Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, the Brain and Cognition Discovery Foundation, the Canadian Cancer Society, the Canadian Institute of Health Research (CIHR), the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, Labatt Brain Health Network, Physician Services Inc. (PSI) Foundation, the University Health Network Centre for Mental Health, the University of Toronto, and Timeposters Fellowship; he has received industry funding for speaker/consultation/research fees from Allergan, Boehringer Ingelheim, Compass, iGan, Janssen, Lundbeck, and Sunovion; and he previously served as chief medical and scientific officer of Braxia Scientific Corp. The other authors report no financial relationships with commercial interests.